Skip to content

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
Selina Luger, MD, weighs the promise and challenges of modern ALL care
Advancing care through collaborative science: A European perspective
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young
Dr. Maddocks previews Friday MCL session at SOHO 2026

Insider Reader Survey

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

September 13, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Elias Jabbour, MD

Elias Jabbour, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
717 Views
2 years ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Doctor holding an ipad

Acute Lymphoblastic Leukemia News, SOHO 2026

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

September 11, 2026

Acute Lymphoblastic Leukemia News, SOHO 2026, Meetings / Conferences

Selina Luger, MD, weighs the promise and challenges of modern ALL care

September 11, 2026

SOHO 2026, Meetings / Conferences

Advancing care through collaborative science: A European perspective

September 11, 2026

MDS News, SOHO 2026, Trending now, Meetings / Conferences, News

SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young

September 10, 2026

SOHO 2026, News

Dr. Maddocks previews Friday MCL session at SOHO 2026

September 10, 2026

Lymphoma News, SOHO 2026, Meetings / Conferences

Unmet treatment needs in relapsed or refractory DLBCL

September 10, 2026

Top Categories

Cellular Therapy

82

Leukemia

133

Lymphoma

141

Multiple Myeloma

120

Myelodysplastic Syndromes

49

Myeloproliferative Neoplasms

36

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Elias Jabbour, MD

Cellular Therapy

Elias Jabbour, MD

Leukemia

Elias Jabbour, MD

Lymphoma

Elias Jabbour, MD

Multiple Myeloma

Elias Jabbour, MD

Myelodysplastic Syndromes

Elias Jabbour, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Doctor holding an ipad

Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status

Selina Luger, MD, weighs the promise and challenges of modern ALL care

Advancing care through collaborative science: A European perspective

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.